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Abstract  2 
Whole tumor cell lysates (TCL) have been implemented as tumor antigens for 3 
cancer vaccine development, although clinical outcomes of TCL-based antitumor 4 
immunotherapy remain unsatisfactory. In order to improve the efficacy of TCL-based 5 
vaccines, biomaterials have been employed to enhance antigen delivery and 6 
presentation. Here, we have developed chitosan nanoparticles (CTS NPs) with surface 7 
mannose (Man) moieties for specific dendritic cells (DCs) targeting (Man-CTS NPs). 8 
The Man-CTS NPs were then loaded with TCL generated from B16 melanoma cells 9 
(Man-CTS-TCL NPs) for in vitro and in vivo assessment. Potency of the 10 
Man-CTS-TCL NPs as cancer vaccine was also assessed in vivo by immunization of 11 
mice with Man-CTS-TCL NPs followed by re-challenge with B16 melanoma cell 12 
inoculation. We have shown here that Man-CTS-TCL NPs promote bone 13 
marrow-derived dendritic cells (BMDCs) maturation and antigen presentation in vitro. 14 
In vivo evaluation further demonstrated that the Man-CTS-TCL NPs were readily 15 
taken up by endogenous DCs within the draining lymph node (DLN) following 16 
subcutaneous administration accompanied by increase in serum IFN-γ and IL-4 levels. 17 
Tumor growth was also significantly delayed in mice primed with Man-CTS-TCL 18 
NPs vaccine, attributable at least in part to cytotoxic T lymphocytes response. 19 
Moreover, Man-CTS-TCL NPs vaccine also exhibited therapeutic effects in mice with 20 
melanoma. Thus, we report here the Man-CTS-TCL NPs as effective anti-tumor 21 
vaccine for cancer immunotherapy.  22 
3 
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1. Introduction  1 
Cancer immunotherapy is now considered a promising therapeutic approach against 2 
melanoma, leukemia, prostate and breast cancer [1-3]. The main purpose of this 3 
strategy is to prime naïve T cells and evoke long-term memory CD8+ T cells that 4 
attack tumor cells. Sufficient tumor antigen presentation, often by the antigen 5 
presenting cells (APCs) via the major histocompatibility complex (MHC) class I or II 6 
pathways, is critical in eliciting effective activation of both CD8+ and CD4+ T 7 
lymphocytes and thus determines the therapeutic efficacy of antitumor 8 
immunotherapy [4-6].  9 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) and are 10 
experts in priming T cells-mediated immunity [7,8]. DCs-based vaccine has been 11 
extensively investigated as a feasible approach to enhance antigen-specific immune 12 
responses [6]. Most previous studies aimed at developing tumor vaccines that activate 13 
cytotoxic T lymphocytes (CTLs) responses and antibody secreting B cells through 14 
DCs mediated antigen presentation [9,10]. However, despite promising preliminary 15 
data, clinical outcomes of tumor vaccines have been disappointing [11,12]. One major 16 
challenge of the current antitumor immunotherapy is inefficient antigen delivery and 17 
subsequent induction of T cell mediated immune responses. In addition, the 18 
electrofusion process of DCs and tumor cells is time-consuming and laborious [13]. 19 
Moreover, external pulsing of DCs with selective peptides only results in limited 20 
stimulation of T cells due to the rapid turnover of class I peptides complex on the cell 21 
surface [14].  22 
5 
It has been recently shown that the use of whole tumor cell lysates preparation can 1 
overcome the above drawbacks and offers a comprehensive source of potential tumor 2 
antigens by inducing CTL responses and CD4+ T helper cell activation [15,16]. 3 
Several clinical trials have used tumor cell lysates for in vitro DC priming [17,18]. 4 
However, soluble tumor lysates containing antigens and cytokines are inherently 5 
unstable and tend to result in poor DCs uptake, inefficient antigen cross-presentation, 6 
and limited induction of CTL response [19]. Recent strategies for developing 7 
prophylactic or therapeutic vaccines have mainly focused on improving in vivo 8 
antigen delivery to specific DCs and prolonging their activation.   9 
Biomaterial encapsulation of antigens has been proposed as a promising strategy to 10 
enhance immunogenicity during vaccination [20]. Not only could biomaterial 11 
encapsulation protect the antigens from degradation during in vivo administration, it 12 
also enables controlled release of antigens in a desired manner [21-24]. Moreover, 13 
surface of biomaterials could be modified with ligands or antibodies that are 14 
specifically recognized by DCs and used for DC targeting [25].  15 
Chitosan is a cationic polysaccharide primarily derived from the exoskeletons of 16 
crustaceans and extensively used as vaccine delivery vehicles [21,26,27]. Earlier 17 
studies have reported chitosan-based nanoparticles, with particle size ranging from 18 
100 to 500 nm, as feasible vehicles for in vivo delivery of proteins or peptides [28]. 19 
Moreover, chitosan nanoparticles have been reported to elicit significant adjuvant 20 
effect by stimulating innate immune responses [29]. Given the potential 21 
pro-inflammatory property of chitosan, we have developed chitosan nanoparticles 22 
6 
with surface-decorated mannose (Man-CTS NPs) for specific DC targeting. Indeed, 1 
studies have shown that nanoparticles with surface-decorated mannose are effective 2 
delivery vehicles for APCs targeting [30-32]. Since the mannose receptor is expressed 3 
by immature dendritic cells, the mannose moiety on the surface of the Man-CTS NPs 4 
can be detected by DCs, via which antigen uptake would be enhanced [33,34]. Thus, 5 
in the present study, targeted delivery of Man-CTS-TCL NPs was assessed both in 6 
vivo and in vitro. In addition, to evaluate the potential of Man-CTS NPs as cancer 7 
vaccine delivery vehicle, we also encapsulated tumor cell lysates generated from B16 8 
melanoma cells (Man-CTS-TCL NPs) and in vivo assessment of Man-CTS-TCL NPs 9 
on tumor prevention was performed.  10 
2. Material and methods  11 
2.1. Reagent and antibodies  12 
Chitosan (CTS, Mw = 50,000, DD (degree of deacetylation) > 95%) was supplied 13 
by Ao'xing Biotechnology Co., Ltd. (Zhejiang, China), and used without further 14 
purification. Sodium alginate (ALG, viscosity: 160 mpa·s, 20 ℃, 1% aqueous solution) 15 
was supplied by Qingdao Crystal Rock Biology Development Co., Ltd. (Qingdao, 16 
China). Tetrabutylammonium (TBA) hydroxide and 4-Aminophenyl 17 
α-D-mannopyranoside (MAN) were purchased from Aladdin (Shanghai, China). 18 
2-chloro-1-methylpyridinium iodide (CMPI) was obtained from Alfa Aesar (Tianjin, 19 
China). Sodium sulfate, polysorbate 80 (Tween 80) and acetic acid were purchased 20 
from Sigma (St. Louis, MO). The MicroBCA™ Protein assay kit was supplied by 21 
Thermo Fisher Scientific Inc. (Rockford, IL USA). Phosphate Buffered Saline (PBS) 22 
7 
(1×), RPMI-1640 medium, heat inactivated fetal bovine serum (FBS), trypsin EDTA 1 
0.05%, penicillin/streptomycin (PEST) 10,000 Unit/mL/10,000 µg/mL, sodium 2 
pyruvate 100 mM, HEPES 1 M, 2-mercaptoethanol 50 mM, ACK lysing buffer and 3 
AlamarBlue® reagent were purchased from Life Technologies (Carlsbad, CA, USA). 4 
All the other chemicals were of analytical grade. 5 
Anti-mouse ELISA kits IFN-γ, IL-4, IgG and IL-12p70 were purchased from 6 
eBioscience. Recombinant mouse GM-CSF and IL-4 were purchased from Peprotech 7 
(Rocky, Hill, USA). Fluorochrome-labeled anti-mouse monoclonal antibodies (CD3e, 8 
CD4, CD8a, CD80, CD86, MHCI, MHCII, CD11c, CD40 and CCR7) were purchased 9 
from eBioscience (CA, USA).  10 
2.2. Cell lines and animals 11 
Female C57BL/6 (6-8 weeks old) and female Balb/c mice (6-8 weeks old) were 12 
purchased from (Academy of Military Medical Sciences, Beijing, China). All animal 13 
procedures were reviewed and ethically approved by Center of Tianjin Animal 14 
Experiment ethics committee and authority for animal protection (Approval No.: 15 
SYXK (Jin) 2011-0008). Mouse B16 melanoma tumor cell line [35] was purchased 16 
from the Cell Bank of China Academy of Sciences, and cultured according to the 17 
manufacture’s guidelines.  18 
2.3. Generation and isolation of tumor cell lysates 19 
Tumor cell lysates (TCL) were generated as previously described [36]. Briefly, B16 20 
melanoma tumor cell pellets were re-suspended in ice cold phosphate-buffered saline 21 
(PBS) at a 1×107/ml cell density and subjected to five freeze-thaw cycles of rapid 22 
8 
freezing in liquid nitrogen (for 5 min) and thawing at 37 ℃ (for 5 min). The lysates 1 
were then centrifuged at 2,000 g for 10 min to remove cellular debris. Protein 2 
concentrations were measured by BCA assay and the concentrated protein solution 3 
was diluted to appropriate concentration for in vivo and in vitro experiments. 4 
2.4. Preparation of mannose-modified alginate (Man-ALG) 5 
Tetrabutylammonium-alginate (ALG-TBA) was synthesized as previous report [37]. 6 
500 μg (1.190 mmol) ALG-TBA was dissolved in 50 mL of anhydrous 7 
dimethylformamide (DMF). 152.1 mg CMPI (0.595 mmol) was added to activate the 8 
ALG-TBA in nitrogen at 0 ℃. After 1 h, 4-Aminophenyl α-D-mannopyranoside 9 
(0.357 mmol) was added at room temperature and leave to react for 24 h. The reaction 10 
mixture was precipitated in absolute ethanol, repeatedly dissolved and precipitated for 11 
three times. The Man-ALG solution was transferred to a dialysis bag (MW=3500 Da) 12 
to dialyze in distilled water for 2 days. The final product of Man-ALG was obtained 13 
after freeze-drying. The chemical structure of Man-ALG was confirmed by 1H NMR 14 
spectroscopy (Varian Mercury 400, USA) and IR spectroscopy (Spectrum Instruments 15 
Co., Ltd. Brook Germany). The substitution degree (SD) of Man was defined as the 16 
ratio of reacted sugar unit to the total sugar unit of ALG. 17 
2.5. Preparation and characterization of mannose-decorated chitosan 18 
nanoparticle encapsulation of tumor cell lysates (Man-CTS-TCL NPs) 19 
Chitosan and tumor cell lysates (TCL) were dissolved in 1% acetic acid and 20 
ultrapure water, respectively. One mg/mL of chitosan solution and 1 mg/mL of TCL 21 
were obtained. The TCL solution was added drop-by-drop into chitosan solution and 22 
9 
mixed at 1:1 (w/w). The mixture was then agitated at 300 rpm for 30 min to obtain 1 
chitosan/tumor cell lysates complex, which were collected by centrifugation and 2 
dissolved in PBS for experimental use. The Man-ALG solution (1 mg/ml) was added 3 
drop-by-drop into CTS-TCL NPs suspension to obtain mannose decorated CTS-TCL 4 
NPs (Man-CTS-TCL NPs) through electrostatic interaction. Man-CTS-TCL NPs were 5 
collected by centrifugation and suspended in PBS (pH 7.4) for further use. The same 6 
protocol was followed for CTS-TCL NPs preparation except alginate (1 mg/ml) was 7 
added instead of Man-ALG. The method for CTS NPs and Man-CTS NPs is the same 8 
with Man-CTS-TCL NPs although TCL was not added for CTS NPs and Man-CTS 9 
NPs.  10 
Morphology of the nanoparticles was determined by transmission electron 11 
microscopy (TEM, Philips-FEI TecnaiT10, USA). The average particle size, size 12 
distributions, and surface charges of nanoparticles were measured respectively by a 13 
90plus particle sizer and Zeta potential analyzer (Nano-ZS 90, Malvern Instrument, 14 
UK). 15 
2.6. Assessment of antigens release from Man-CTS-TCL NPs  16 
The amount of TCL released from Man-CTS-TCL NPs was measured under acidic 17 
(pH 5.0) and neutral (pH 7.4) condition. Four mg of Man-CTS-TCL NPs were 18 
suspended in 4 mL of PBS and incubated at 37 ℃ with continuous agitation in an 19 
orbital shaker. The suspension was centrifuged at 12000 rpm for 10 min at designated 20 
time points. Three mL of supernatants were collected and stored at -80 ℃ for assaying 21 
later. Then 3 mL of fresh PBS was added to the original tube for further incubation. 22 
10 
Supernatant samples were tested for total protein using BCA protein assay according 1 
to the manufacturer’s instruction. Absorbance at 562 nm was measured using a 2 
microplate reader (Varioskan LUX multimode reader, Thermo Scientific, USA); 3 
proteins concentration was calculated according to standard curve. Cumulative release 4 
was studied for 72 h. The amount of proteins released at different time points was also 5 
calculated respectively.   6 
2.7. Generation and stimulation of bone marrow derived dendritic cells (BMDCs) 7 
in vitro 8 
BMDCs were isolated from hind limb bones of mice using published protocol 9 
[38,39]. Briefly, both distal bone ends were excised and the marrow cells were flushed 10 
using RPMI 1640 (Gibco, Grand Island, NY). The red blood cells were lysed and the 11 
remaining cells were centrifuged at 1500 rpm for 10 min. 2×106/mL cells were 12 
aliquoted in RPMI 1640 supplemented with 10% FBS, 2 mmol/L L-glutamine, 1 13 
mmol/L sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, 20 ng/mL of 14 
GM-CSF (PeproTech) and 10 ng/mL of IL-4 (PeproTech) at 37 ℃. Cells were cultured 15 
in six-well plates in complete medium with cytokines at 4×106 cells/2 mL/well. At day 16 
5 of culturing, TCL, Man-CTS NPs or Man-CTS-TCL NPs were added to make final 17 
concentration of 10 μg/ml, and cultured for 2 more days. On day 7, most of the 18 
non-adherent cells have acquired typical dendritic morphology, and these cells were 19 
used as the source of DCs in subsequent experiment. At this time point supernatant 20 
from different cultures were collected and stored at -80 ℃ for cytokines determination.     21 
For flow cytometry, cells cultured for 7 days were rinsed three times with PBS and 22 
11 
briefly trypsinized to form a single cell suspension. Cells were stained for 30 min on 1 
ice with following fluorescence-labeled antibodies (1 µg/2×106 cells): Anti-mouse 2 
MHCI (H-2Kb)-FITC (clone: AF6-88.5.5.3), Anti-mouse MHCII (clone: AF6-120.1), 3 
Anti-mouse CD11c PE-Cy7 (clone: N418), Anti-mouse CD86 APC (clone: GL1), 4 
Anti-mouse CD80 FITC (clone: 16-10A1), Anti-mouse CD40 PE (clone: 1C10), 5 
Anti-mouse CCR7 PE (clone: 4B12). Cells were then washed twice with cold PBS 6 
and analyzed on a four color BD Accuri C6. Data analysis was performed using BD 7 
Accuri C6 software (BD biosciences, San Jose, CA).   8 
2.8. Flow cytometry analysis of antigens uptake by BMDCs and the intracellular 9 
localization of antigen in BMDCs 10 
The methods for FITC-labeled TCL (TCL-FITC), TCL-FITC loaded CTS 11 
nanoparticles (CTS-TCL-FITC NPs) and TCL-FITC loaded Man-CTS nanoparticles 12 
(Man-CTS-TCL-FITC NPs) preparation are detailed in supporting information.         13 
Immature BMDCs were cultured with TCL-FITC, CTS-TCL-FITC NPs or 14 
Man-CTS-TCL-FITC NPs at 37 ℃ for 2, 4, 6, 12, 24 and 48 h. The surface binding of 15 
TCL-FITC by BMDCs was determined by measuring mean fluorescence intensity 16 
(MFI) using flow cytometry.   17 
BMDCs (1×106 cells/mL) were cultured with TCL-FITC, CTS-TCL-FITC NPs or 18 
Man-CTS-TCL-FITC NPs at 37 ℃ for 4 h. At the end of the experiment, the cells 19 
were labeled with 50 nM Lyso Traker Red DND-99 (Invitrogen, CA, USA) for 60 min 20 
to visualize late endosomes and lysosomes. The nuclei were stained with DAPI 21 
(Sigma, MO, USA) for 5 min and fluorescent images were recorded by a confocal 22 
12 
laser scanning microscopy (TCS SP5II, Leica, Ernst-Leitz-Strasse, Germany).   1 
2.9. In vivo trafficking analysis of Man-CTS-TCL NPs  2 
Near-Infrared Cyanine 7 dyes were used to label TCL. The methods of Cy7 labeled 3 
TCL (TCL-Cy7), TCL-Cy7 loaded CTS nanoparticles (CTS-TCL-Cy7 NPs) and 4 
TCL-Cy7 loaded Man-CTS nanoparticles (Man-CTS-TCL-Cy7 NPs) preparation are 5 
included in supporting information.  6 
Balb/c mice were injected subcutaneously with TCL-Cy7 (50 µg), CTS-TCL-Cy7 7 
NPs containing 50 µg TCL-Cy7 or Man-CTS-TCL-Cy7 NPs containing 50 µg 8 
TCL-Cy7 dispersed in 100 µl PBS. Vaccine kinetics was then studied at several time 9 
points after administration by a small animal in vivo imaging system (Maestro, CRI 10 
USA). Mice were anesthetized by inhalation of isoflurane and fluorescence spectral 11 
cubes were acquired using near infrared (illumination light from 700 nm to 900 nm in 12 
10 nm steps at 2 s exposure for each step Exp.700 nm to 760 nm, Emission 800 nm 13 
long pass) preset filter combinations. Unmixed images in which background signals 14 
were subtracted and quantified by using Maestro software. Kinetics was measured by 15 
quantifying the fluorescent intensity in pre-set regions of interest (ROI) at the 16 
injection site and the draining inguinal lymph node. The fluorescence signal in the 17 
injection site at each time point was presented as the percentage of the maximum 18 
recorded value, to show percent decrease in time [40].   19 
2.10. In vivo immunization, cytokines secretion, and T lymphocytes proliferation 20 
assay 21 
C57BL/6 mice were immunized 3 times with PBS (control), TCL, CTS NPs, 22 
13 
Man-CTS NPs, CTS-TCL NPs and Man-CTS-TCL NPs group by subcutaneous (s.c.) 1 
injection at days -14, -13 and -7. The dose of TCL in each group was 100 µg/mouse. 2 
Blood was collected 7 days after last immunization for cytokines and antibody 3 
analysis, cytokines of IFN-γ, IL-4, IL-12p70 and TCL antigens specific IgG antibody 4 
in serum was determined by ELISA (eBioscience). For analysis of tumor specific IgG 5 
antibody, using 10 µg/mL total tumor cell lysates coating the plate to test tumor 6 
antigens specific IgG antibody.  7 
For in vitro T lymphocytes proliferation assay, splenic T cells were isolated from 8 
C57BL/6 mice of all treatment groups 7 days after last immunization and labeled with 9 
5 µmol/L 5, 6-carboxyfluorescein acetate N-succinimidyl ester (CFSE, Sigma-Aldrich) 10 
according to the manufacturer’s instructions. The CFSE-labeled T cells (4×106 11 
cells/mL) were then incubated with 10 µg/mL soluble TCL antigens for re-stimulation 12 
of antigen-specific memory T cells responses and maintained in culture for 5 days. T 13 
cells were then collected and T lymphocyte proliferation was assessed by flow 14 
cytometry. Percentages of CD4+ CFSElow and CD8+ CFSElow T cells were analyzed. 15 
2.11. Immunization and tumor challenge  16 
Female C57BL/6 6-8 weeks old mice were randomized into one of the following 17 
treatment groups (n=6): (1) Control group, (2) TCL group, (3) CTS NPs group, (4) 18 
Man-CTS NPs group, (5) CTS-TCL NPs group and (6) Man-CTS-TCL NPs group. 19 
Mice received 3 subcutaneous injections of 100 µL (concentration was 1 mg/mL) of 20 
vaccine at days -14, -13 and -7 in the left flank followed by inoculation with 1×105 21 
B16 cells suspended in 50 µL PBS in the right side. The day of inoculation was 22 
14 
counted as day 0 followed by the closely monitored at every other day for 1 
pain/distress, tumor volume and body weight. Tumor growth was evaluated by 2 
measuring two perpendicular tumor dimensions using a caliper. Tumor volumes (V, 3 
mm
3) were calculated using the following formula: V=1/2(W2×L), where W (width) is 4 
the perpendicular dimension to the length, L (length) is the longest dimension. Mice 5 
were sacrificed at day 21. Tumors were removed and weighted. Spleen and lymph 6 
nodes were excised and made into single cells suspension for flow cytometer analysis 7 
of T cells subpopulations.  8 
2.12. CTL assays 9 
Single cell suspensions of splenocytes were prepared from mice 21 days after B 16 10 
melanoma cell inoculation. Cells were seeded onto 6-well plates (~1×107 cells/well) 11 
and co-cultured with B16 cells (~1×106 cells/well) for 72 hours. The appropriate 12 
numbers of effector (E) cells were incubated with 6000 fresh target (T) B16 cells with 13 
E:T ratios varied at 10:1 to 50:1 in each well of U-bottomed 96 well plates. The 14 
mixture were then incubated for 4 h at 37 ℃ in 95% O2/5% CO2 and the lactate 15 
dehydrogenase levels in cell culture supernatants were tested by CTL assay kit 16 
following the manufacture’s (Promega) instruction [41, 42].  17 
2.13. In vivo assessment of antitumor effect of the M-CTS-TCL NPs 18 
Female C57BL/6 6-8 weeks old mice were s.c. injected in the right flanks with 1×19 
105 B16 cells suspended in 50 µL PBS. On day 7, mice were randomly assigned into 20 
six groups (n=6 in each group). On day 7, 14, and 21 post tumor inoculation, mice 21 
were s.c. immunized with PBS (Group 1), TCL (Group 2), CTS NPs (Group 3), 22 
15 
Man-CTS NPs (Group 4), CTS-TCL NPs (Group 5) and Man-CTS-TCL NPs (Group 1 
6). The day on which B16 melanoma cell inoculation was performed as day 0. Mice 2 
were closely monitored every other day for pain/distress, tumor volume and body 3 
weight. Tumor growth was evaluated by measuring two perpendicular tumor 4 
dimensions using a caliper. Tumor volumes (V, mm3) were calculated using the 5 
following formula: V=1/2(W2×L), where W (width) is the perpendicular dimension to 6 
the length, L (length) is the longest dimension. Mice were sacrificed at day 22. Sera 7 
were collected for IFN-γ and IL-4 ELISA analysis. Tumors were removed and 8 
weighted and spleens were excised for flow cytometer analysis of T cells 9 
subpopulations.    10 
2.14. Statistical analysis 11 
Data are presented as mean ± standard deviations. The differences between the 12 
control group and experimental groups were assessed using a student’s t-test, and the 13 
differences between groups were determined by one-way ANOVA and Tukey’s 14 
posttest (GraphPad Software, La Jolla, CA, USA).  15 
3. Results and Discussion  16 
3.1. Preparation and Characterization of Man-CTS-TCL NPs 17 
Due to its anionic property, CTS NPs was synthesized for TCL encapsulation, 18 
forming a CTS-TCL complex, which was further coated with mannose-modified 19 
alginate (Man-ALG). The synthesis route of Man-ALG is shown in (Fig.1A) and the 20 
structure of Man-ALG was confirmed by FT-IR (Fig.1B). As clearly shown in Fig. 1B, 21 
the peaks observed at 1616 cm−1 and 1418 cm−1 are characteristic carboxylate of the 22 
16 
absorption bands of ALG. After mannose modification, the peaks at 1670 cm−1 (amide 1 
band I) and 1510 cm−1 (amide band II) could be observed, indicating formation of 2 
amide bonds. Fig.1C shows the 1H NMR spectra of ALG and Man-ALG. Small peaks 3 
shown at 7.0-7.5 ppm are representative of typical protons of the 4-Aminophenyl 4 
α-D-mannopyranoside moiety, demonstrating successful conjugation of Man to ALG. 5 
The substitution degree of Man in Man-ALG was 8.4%, i.e. an average of 8.4 Man 6 
moieties per 100 sugars units of ALG.  7 
Physical characteristics of nanoparticles, including the average particle size, size 8 
distributions, and surface charges of nanoparticles were summarized in Supporting 9 
Information (Table S1). The average diameter of Man-CTS-TCL NPs was 120 nm and 10 
spherical in shape with an overall charge of -12 mV (Fig.1D&E). The protein 11 
releasing kinetics was determined in vitro and shown in Fig.1F, elevated and more 12 
sustained protein release could be detected when the surrounding pH values was 5.0, 13 
suggesting a better releasing property of the Man-CTS-TCL NPs in the acidic 14 
environment of the endo/lysosomes.  15 
3.2. Man-CTS-TCL NPs promoted antigen uptake in BMDCs  16 
The efficacy of Man-CTS-TCL NPs on antigen uptake was initially examined in 17 
BMDCs. TCL-FITC, CTS-TCL-FITC NPs and Man-CTS-TCL-FITC NPs were 18 
incubated with BMDCs for 2, 4, 6, 12, 24 or 48 h. Antigen uptake partly through 19 
surface binding was quantified by MFI of FITC as measured flow cytometry. Cellular 20 
localization of TCL-FITC was examined by confocal fluorescent microscopy. As 21 
shown in Fig. 2B&C, a 3-fold increase of FITC-TCL uptake was observed in BMDC 22 
17 
co-cultured with Man-CTS-TCL-FITC NPs as compared controls (MFI: 82.0339±1 
9.0000 [×104]). As expected, the fluorescence signal of FITC which corresponds to 2 
DC antigen uptake decreased over time in all groups. These results suggest that 3 
compared to TCL and CTS-TCL NPs, Man-CTS-TCL NPs can significantly increase 4 
antigens uptake of BMDCs, partly via enhanced surface binding. In addition, for 5 
clarification fluorescence spectra of TCL-FITC, CTS-TCL-FITC NPs and 6 
Man-CTS-TCL-FITC NPs are presented in supporting information (Fig. S1). 7 
3.3. Man-CTS-TCL NPs induce BMDC maturation  8 
To further investigate the effect of Man-CTS-TCL NPs on DCs in vitro, immature 9 
BMDCs were harvest on day 5 after isolation and exposed to Man-CTS-TCL NPs for 10 
48 h. Fig.3A&B shows the microscopic views of mature DCs in microscope. DC 11 
maturation was characterized by surface marker expression using flow cytometry, and 12 
we found that exposure to Man-CTS-TCL NPs significantly enhanced expression 13 
levels of CD80, CD86 and CD40, surface markers that indicates DC maturation 14 
(Fig.3C&D). Moreover, the expression levels of MHC I, MHC II, and CCR7 were 15 
also upregulated in DCs treated with Man-CTS-TCL NPs (Fig.3E&F), all of which 16 
are demonstrative of a facilitative role of Man-CTS-TCL NPs on DC maturation.  17 
3.4. In vivo imaging of Cyanine 7 labeled Man-CTS-TCL NPs  18 
In order to investigate the effect of Man-CTS-TCL NPs on endogenous DC 19 
activities, TCL-Cy7, CTS-TCL-Cy7 NPs and Man-CTS-TCL-Cy7 NPs were 20 
administrated by subcutaneous (s.c) injection at the tail base site and the presence of 21 
TCL-Cy7, CTS-TCL-Cy7 NPs and Man-CTS-TCL-Cy7 NPs were then visualized at 22 
18 
the injection site and in the adjacent draining lymph node (DLN), where immune 1 
responses are initiated [43]. We selected tail base as injection site which is able to 2 
distinguish from the lymph nodes and it drains specifically to the inguinal lymph node 3 
(ILN) [44]. Fig.4A shows representative images of fluorescence signals corresponding 4 
to TCL-Cy7, CTS-TCL-Cy7 NPs and Man-CTS-TCL-Cy7 NPs at the injection site 5 
and the ILN (Fig.4A red arrows) at designated time points. The fluorescence signals 6 
were quantified and the average fluorescence were plotted against time and presented 7 
in Fig.4B. Improved migratory ability of Man-CTS-TCL-Cy7 NPs to the ILN was 8 
evident as compared to TCL-Cy7 and CTS-TCL-Cy7. Furthermore, accumulation of 9 
free TCL was observable in the liver of TCL-only group whilst for CTS-TCL NPs 10 
group; the fluorescence signal was detected not just within the ILN, but also in 11 
adjacent tissues. No signal of Cy 7 could be recorded in the ILN at 24 h following 12 
injection in both TCL and CTS-TCL NPs group, in contrast to the Man-CTS-TCL 13 
NPs group, where robust and sustained Cy 7 signal was detectable at 24 h following 14 
injection. One explanation for the migratory advantage of Man-CTS-TCL-Cy7 NPs is 15 
that both active and passive pathways are involved during antigen migration from the 16 
tail back to the right inguinal DLN [28]. This is consistent with previous study 17 
reporting that nanoparticles with comparatively smaller size facilitate DC uptake by 18 
passive cellular endocytosis [45]. Since the average size of Man-CTS-TCL NPs is 19 
approximately 100 nm, it is possible that the nanoparticles are taken up by resident 20 
DCs passively in addition to active uptake as a result of the mannose interaction.   21 
3.5. Effect of Man-CTS-TCL NPs on endogenous DCs maturation and antigen 22 
19 
presentation at the draining lymph node  1 
To assess the efficacy of Man-CTS-TCL NPs as potential cancer vaccine, mice 2 
were administrated with Man-CTS-TCL NPs, CTS-TCL NPs, Man-CTS NPs, CTS 3 
NPs or TCL only by s.c. injection at days -14, -13 and -7. Non-treated mice were also 4 
included in parallel as controls. On day 0 and day 7, the draining lymph nodes and 5 
spleen of each mouse were obtained. As shown in Fig.5A, the ILNs from CTS-TCL 6 
NPs group and Man-CTS-TCL NPs group were moderately bigger in size compared 7 
to other groups. DC maturation is associated with a wide range of cellular changes, 8 
such as increased expression of costimulatory molecules, surface MHC class II 9 
molecules, and chemokine receptor (e.g. CCR7), which allow them to migrate to the 10 
LNs [4]. To assess the impact of nanoparticle-delivered TCL antigen on DC 11 
maturation, expression levels of CD11c, CD80, CD86, MHCII and CCR7 on APCs 12 
within the ILNs were analyzed. It is clear from Fig.5B, expressions of CD11c+CD86+, 13 
CD11c+CD80+, CD11c+MHCII+, CD11c+MHCI+ and CD11c+CCR7+ were 14 
upregulated in the Man-CTS-TCL NPs group, significantly elevated as compared to 15 
other groups, indicating more robust impact of the Man-CTS-TCL NPs on stimulating 16 
resident DC maturation within the LNs. Furthermore, results of antigen recall T-cell 17 
proliferation also showed that proliferation of both CD8+ and CD4+ T cells were 18 
elevated from the Man-CTS-TCL NPs exposed group when compared to others. 19 
Proliferation of CD8+ T cells were significantly increased compared with CTS NPs 20 
and Man-CTS NPs, but not the TCL only group. Whilst CD4+ T cell proliferation was 21 
significantly enhanced from the Man-CTS-TCL NPS when compared with TCL group, 22 
20 
CTS NPs and Man-CTS NPs (Fig.5C&D). Similarly, upregulation of IFN-γ and IL-4 1 
was also detected in the sera of mice (Fig.5E&F), confirming T cell activation.  2 
3.6. Man-CTS-TCL NPs as a nano-vaccine exhibited TCL-induced antitumor 3 
immune responses   4 
To examine the antitumor efficacy of Man-CTS-TCL NPs, we immunized C57BL/6 5 
mice with Man-CTS-TCL NPs and re-challenged the mice by inoculation of 1×105 6 
B16 tumor cells. The detailed immunization protocol is included in Supplementary 7 
Fig.S4A. There was no significant difference in mice body weight among those six 8 
groups (Fig.6A). As shown in Fig.6B, administration of Man-CTS-TCL NPs could 9 
significantly delay tumor growth compared with untreated control group, CTS NPs 10 
group, Man-CTS NPs group and mice immunized with TCL, shown by considerably 11 
smaller tumor size by Day 21. What’s more, compared with control group, TCL group, 12 
CTS NPs group, Man-CTS NPs group, and CTS-TCL NPs group, the average tumor 13 
weight in Man-CTS-TCL NPs group was significantly decreased (Fig.6C).   14 
It has been well established that CD8+ T cells are important effector cells in vaccine 15 
induced anti-tumor responses [46]. In line with that, we found that mice immunized 16 
with Man-CTS-TCL NPs showed significantly more CD8+ T cells in the LN and 17 
spleen than other groups (Fig.6E&F). No difference could be detected regarding CD4+ 18 
T cells following immunization among all treatment groups (Data not shown). 19 
Meanwhile, the absolute number of CD3+ T cells in spleen was calculated and no 20 
significant difference could be deduced between Man-CTS-TCL NPs group and 21 
others (Supplementary Fig.S4B). Significant elevation of the absolute number of 22 
21 
CD3+CD8+ T cells in spleen was seen in the Man-CTS-TCL NPs group when 1 
compared with others (Supplementary Fig.S4C), all of which emphasize the 2 
importance of CD8+ T cells in Man-CTS-TCL NPs-induced antitumor activity.  3 
3.7. Man-CTS-TCL NPs potently enhanced cytotoxic T lymphocytes (CTL) 4 
responses against tumor  5 
To test the efficacy of T cells in mediating tumor-specific CTL responses, cytotoxic 6 
T lymphocyte (CTL) assay was performed. First, we co-cultured the effector cells 7 
(splenocytes isolated from immunized mice) and the target cells B16 melanoma cells. 8 
Lysis of target cells was then tested at the Effector:Target (E:T) cell ratio of 10:1, 20:1 9 
and 50:1. Importantly, the effector T cells isolated from mice immunized with 10 
Man-CTS-TCL NPs lysed ~35%  target melanoma cells, while the lysed target 11 
melanoma cells in control group was only ~12% (Fig.6D). This showed that mice 12 
immunized with Man-CTS-TCL NPs were more efficient in inducing CTL response 13 
against the B16 melanoma target cells.  14 
3.8. Man-CTS-TCL NPs achieved therapeutic effects in melanoma tumor model  15 
  To investigate the therapeutic effect of Man-CTS-TCL NPs, C57BL/6 mice were 16 
inoculated s.c. with 1×105 B16 melanoma cells 7 days before vaccination with 17 
Man-CTS-TCL NPs. Detailed protocol is shown in Supplementary Fig.S5A. There 18 
was no significant difference in mice body weight among all groups (Fig.7A). As 19 
shown in Fig.7B, vaccination with Man-CTS-TCL NPs significantly inhibited B16 20 
tumor growth, compared with PBS-administrated controls. Consistently, tumor weight 21 
in Man-CTS-TCL NPs group was significantly decreased at day 22 compared to 22 
22 
control group, although no differences could be observed between other groups and 1 
control (Fig 7C). Expression of mouse serum IFN-γ was consistent with the 2 
anti-tumor results (Fig.7E). Compared with other groups, mice in Man-CTS-TCL NPs 3 
group showed more CD8+ T cells in spleen (Fig.7F), with no difference detectable 4 
regarding the absolute number of CD3+ T cells in spleen (Supplementary Fig.S5B). 5 
Significant increase of the absolute number of CD3+CD8+ T cells in spleen was 6 
observed in Man-CTS-TCL NPs when compared to others (Supplementary Fig. S5C). 7 
These results suggest that Man-CTS-TCL NPs exhibit therapeutic efficacy in mice 8 
with melanoma, and it may provide a translational option as immunotherapy.   9 
4. Conclusion  10 
In summary, we demonstrate here chitosan-based nanoparticles with surface 11 
-decorated mannose, Man-CTS NPs as potential vehicle for cancer vaccine delivery. 12 
Furthermore, by encapsulating TCL generated from B16 melanoma cells, we further 13 
showed the Man-CTS-TCL NPs as potent cancer vaccine for tumor prevention. The 14 
robust antitumor effect of Man-CTS-TCL NPs could be partly attributed to effective 15 
stimulation of cellular and humoral antitumor immunities by the nanoparticles. In 16 
addition, we also demonstrate the possibility of using mannose as effective DC 17 
targeting ligand by conjugation of mannose with biomaterials to facilitate DC 18 
maturation, antigen uptake and presentation. Thus, we report here chitosan-based 19 
nanoparticles with surface-decorated mannose as antigen delivery vehicle that 20 
improves the efficacy of antitumor immune responses than CTS-TCL NPs and TCL 21 
alone. The Man-CTS-TCL NPs could therefore be considered a feasible therapeutic 22 
23 
approach as development of cancer vaccine.  1 
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Figure Legend 22 
Figure 1 Preparation and characterization of mannose decorated chitosan 23 
nanoparticle encapsulation of tumor cell lysates. (A) Scheme of Man-ALG 24 
preparation. (B) FT-IR spectra of Man-ALG. (C) 1H-NMR spectra of Man-ALG in 25 
D2O. (D) The size distribution of Man-CTS-TCL NPs. (E) The TEM image of 26 
Man-CTS-TCL NPs. (F) Protein released from Man-CTS-TCL NPs in PBS at 27 
different pH values. 28 
28 
Figure 2 Mannose-decorated CTS-TCL NPs enhance bone marrow dendritic 1 
cells uptake of antigens in vitro. (A) DCs were incubated with FITC-labeled TCL, 2 
CTS-TCL NPs, and Man-CTS-TCL NPs for 4 h, then labeled with lysoTacker-Red to 3 
identify late endosomes and lysosomes, and labeled with DAPI for cell nucleus. The 4 
uptake of nanoparticles was detected by confocal microscopy. Scale bars, 25 µm. Data 5 
are representative of three independent experiments. (B-C) DCs were incubated with 6 
FITC-labeled TCL, CTS-TCL NPs, and Man-CTS-TCL NPs for 2, 4, 6, 12, 24 and 48 7 
h, the histogram of mean fluorescence intensity (MFI) of BMDCs was detected by 8 
flow cytometry. Data are representative of three independent experiments. *P<0.05, 9 
**P<0.01 and ***P<0.001, Man-CTS-TCL NPs group compared with other groups. 10 
Figure 3 Effect of mannose-decorated CTS-TCL NPs on mouse bone marrow 11 
dendritic cells maturation and antigen presentation in vitro. (A-B) Representative 12 
microscopic views of BMDCs maturation stimulated with TCL (A), Man-CTS-TCL 13 
NPs (B) for 48 h. Scale bar: 25 µm. (C-D) BMDCs were analyzed for expression of 14 
CD80, CD86, CD11c and CCR7 by flow cytometry after stimulated with TCL, 15 
Man-CTS NPs or Man-CTS-TCL NPs for 48 h. Data are representative of three 16 
independent experiments. (E-F) BMDCs were analyzed for expression of MHCI, 17 
MHCII, CD11c and CD40 by flow cytometry after stimulated with TCL, Man-CTS 18 
NPs or Man-CTS-TCL NPs for 48 h. Data are representative of three independent 19 
experiments, *P<0.05, **P<0.01 and ***P<0.001, Man-CTS-TCL NPs group 20 
compared with other groups. 21 
Figure 4 In vivo tracking of Cyanine 7 labeled TCL, CTS-TCL NPs and 22 
29 
Man-CTS-TCL NPs in the injection site and draining lymph node. (A) Presence 1 
of TCL, CTS-TCL NPs and Man-CTS-TCL NPs in the injection site and the right 2 
inguinal draining lymph node, based on quantification of the fluorescent signal of 3 
near infrared coupled to the Cyanine 7. The lymph node is indicated by a red arrow. 4 
Repeated measurements in time plotted on the same scale of fluorescence. (B) The 5 
mean density of Cyanine 7 in the draining lymph node was calculated. All images are 6 
overlays of bright photographs with fluorescence intensity measurements indicated on 7 
the color scale. DLN, draining lymph node; ILN, inguinal lymph node. Data are 8 
representative of three independent experiments.  9 
Figure 5 Effect of Man-CTS-TCL NPs induces immune responses in normal mice. 10 
(A) Draining lymph node was isolated at day 0 after s.c. injection of PBS, TCL, CTS 11 
NPs, Man-CTS NPs, CTS-TCL NPs and Man-CTS-TCL NPs in the right flank of 12 
C57BL/6 mice at day -14, -13 and -7, images of inguinal lymph node in different 13 
treatment groups. (B) Draining lymph node was made into single cell suspensions, 14 
and the expression of major DCs surface markers was analyzed by flow cytometry. 15 
(C-D) Antigen presentation in draining lymph node after immunized with PBS, TCL, 16 
CTS NPs, Man-CTS NPs, CTS-TCL NPs and Man-CTS-TCL NPs for 3 times in vivo. 17 
MHCI and MHCII antigen presentation was determined by measuring CFSE labeled 18 
CD8+ T and CD4+ T cell proliferation (defined as CFSElow), respectively. (E) IFN-γ 19 
released from mice serum was tested by ELISA. (F) IL-4 released from mice serum 20 
was tested by ELISA. Data are representative of three independent experiments. 21 
Differences between Man-CTS-TCL NPs and other groups are analyzed using 22 
30 
one-way ANOVA analysis. *P<0.05, **P<0.01 and ***P<0.001, Man-CTS-TCL NPs 1 
group compared with other groups.  2 
Figure 6 Man-CTS-TCL NPs vaccines induce protection effect in prophylactic 3 
tumor model. (A) Mean body weight during the total immunization course. (B) Mean 4 
tumor growth curves given by tumor volume. (C) The tumor weight was measured 21 5 
days after last immunization. (D) Splenocytes were isolated 21 days after B16 tumor 6 
cells inoculation, co-cultured with B16 cells, and 3 days later used as effector cells for 7 
cytotoxic T lymphocytes (CTL) response assay. (E) Phenotype analysis of CD3+CD8+ 8 
T cells in mice lymph nodes 21 days after B16 tumor cells inoculation. (F) Phenotype 9 
analysis of CD3+CD8+ T cells in mice spleen 21 days after B16 tumor cells 10 
inoculation. Data are representative of three independent experiments. Bars shown are 11 
mean ± SD (n=6), and differences between PBS control group and other groups are 12 
determined using one-way ANOVA analysis and Student’s t test. Relative to control 13 
groups: *P<0.05, **P<0.01 and ***P<0.001. 14 
Figure 7 Man-CTS-TCL NPs vaccines confer therapeutic protection against 15 
melanoma. (A) Mean tumor growth curves given by tumor volume. (B) The tumor 16 
masses of each mouse on 22 days after B16 tumor cells inoculation. (C) The tumor 17 
weight was measured 22 days after tumor challenge. (D) Images of excised tumors 18 
from each mouse in each treatment group by the end of the assay. (E) IFN-γ released 19 
from serum of tumor bearing mice control, TCL, CTS NPs, Man-CTS NPs, CTS-TCL 20 
NPs and Man-CTS-TCL NPs groups was tested by ELISA. (F) Phenotype analysis of 21 
CD3+CD8+ T cells in mice spleen 22 days after B16 tumor cells inoculation. Data are 22 
31 
representative of three independent experiments. Bars shown are mean ± SD (n=6), 1 
and differences between PBS control group and other groups are determined using 2 
one-way ANOVA analysis and Student’s t test. Relative to control group: *P<0.05, 3 
**P<0.01 and ***P<0.001.   4 
5 
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Experimental section 3 
Preparation of FITC labeled tumor cell lysates (TCL-FITC) 4 
Two mg of FITC in 1 mL of 20 mmol/L carbonate buffer (pH 9.5) added to a solution 5 
of TCL (1 mg/mL, 10 mL). The solution was incubated with continuous stirring at 4 6 
oC for 18 h in the dark. The reaction mixture was dialyzed against distilled water 7 
(MWCO 1000) to obtain TCL-FITC.  8 
Preparation and characterization of Man-CTS-TCL-FITC NPs 9 
Three mL of TCL-FITC solution was added drop-by-drop into chitosan solution (1 10 
mg/mL, 1% acetic acid) and mixed at 1:1 (w/w). The mixture was then agitated at 300 11 
rpm for 30 min to obtain TCL-FITC loaded CTS nanoparticles (CTS-TCL-FITC NPs), 12 
which were collected by centrifugation and dissolved in PBS for experimental use. 13 
The Man-ALG solution (1 mg/mL) was added drop-by-drop into CTS-TCL-FITC 14 
NPs suspension to obtain mannose decorated CTS-TCL-FITC NPs 15 
(Man-CTS-TCL-FITC NPs) through electrostatic interaction. Man-CTS-TCL-FITC 16 
NPs were collected by centrifugation and suspended in PBS (pH 7.4) for further use. 17 
Preparation of Cy7 labeled tumor cell lysates (TCL-Cy7) 18 
Two mg of Cy7-NHS in 1 mL of 20 mmol/L carbonate buffer (pH 9.5) was added to a 19 
solution of TCL (1mg/mL, 10 mL). The solution was incubated with continuous 20 
stirring at 4 oC for 18 h in the dark. The reaction mixture was dialyzed against 21 
distilled water (MWCO 1000) to obtain TCL-Cy7. 22 
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Preparation and characterization of Man-CTS-TCL-Cy7 NPs 1 
Three mL of TCL-Cy7 solution was added drop-by-drop into chitosan solution (1 2 
mg/mL, 1% acetic acid) and mixed at 1:1 (w/w). The mixture was then agitated at 300 3 
rpm for 30 min to obtain TCL-Cy7 loaded CTS nanoparticles (CTS-TCL-Cy7 NPs), 4 
which were collected by centrifugation and dissolved in PBS for experimental use. 5 
The Man-ALG solution (1 mg/mL) was added drop-by-drop into CTS-TCL-Cy7 NPs 6 
suspension to obtain mannose decorated CTS-TCL-Cy7 NPs (Man-CTS-TCL-Cy7 7 
NPs) through electrostatic interaction. Man-CTS-TCL-Cy7 NPs were collected by 8 
centrifugation and suspended in PBS (pH 7.4) for further use. 9 
 10 
Results section 11 
Table S1. Characterization of nanoparticles (n=3). 12 
 13 
Sample Size  (nm)  DPI Zeta potentials (mV) 
CTS-TCL NPs 127.46±6.73 0.114±0.031 -14.07±1.22 
Man-CTS-TCL NPs 120.15±9.93 0.121±0.049 -12.07±1.36 
CTS-TCL-FITC NPs 134.72±2.65 0.103±0.051 -15.41±1.25 
Man-CTS-TCL-FITC NPs 136.18±7.63 0.131±0.047 -14.58±1.19 
CTS-TCL-Cy7 NPs 139.16±10.03 0.119±0.039 -15.46±1.52 
Man-CTS-TCL-Cy7 NPs 135.48±8.97 0.124±0.041 -14.92±1.43 
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Figure S1The fluorescence spectra of TCL-FITC, CTS-TCL-FITC NPs and 1 
Man-CTS-TCL-FITC NPs in PBS, and the excitation wavelength is 495 nm. 2 
 3 
Figure S2 The fluorescence spectra of TCL-Cy7, CTS-TCL-C NPs and 4 
Man-CTS-TCL-Cy7 NPs in PBS, and the excitation wavelength is 743 nm. 5 
 6 
Figure S3 Immunization with Man-CTS-TCL NPs produces both cellular and 7 
humoral immune responses in mice. (A) Female C57BL/6 mice (n=6) 6-8 weeks 8 
old were subcutaneously immunized with PBS, TCL, CTS NPs, Man-CTS NPs, 9 
CTS-TCL NPs and Man-CTS-TCL NPs at days -14, -13, and -7. At day 0, serums of 10 
mice were collection and assayed for tumor specific IgG antibody (humoral immune 11 
response) by ELISA. (B) Serums of mice were used for measuring IL-12p70 (cellular 12 
immune response) by ELISA. Data are representative of three independent 13 
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experiments. Bars shown are mean ± SD (n=6), and differences between PBS control 1 
group and other groups are determined using one-way ANOVA analysis and Student’s 2 
t test. Relative to control group: *P<0.05, **P<0.01 and ***P<0.001.   3 
 4 
Figure S4 Immunization of mice with Man-CTS-TCL NPs enhances the absolute 5 
number of CD3+CD8+ T cells in mice spleen. (A) Schedule used for the prophylactic 6 
assay. (B) Number of CD3+ T cells (C) and CD3+CD8+ T cells isolated from spleen 7 
21 days after B16 tumor cells inoculation. Data are representative of three 8 
independent experiments. Bars shown are mean ± SD (n=6), and differences between 9 
PBS control group and other groups are determined using one-way ANOVA analysis 10 
and Student’s t test. Relative to control group: *P<0.05, **P<0.01 and ***P<0.001. 11 
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 1 
Figure S5 In the therapeutic tumor model, Man-CTS-TCL NPs possesses higher 2 
level of the absolute number of CD3+CD8+ T cells in mice spleen. (A) Schedule 3 
used for the therapeutic assay. (B) Number of CD3+ T cells (C) and CD3+CD8+ T cells 4 
isolated from spleen 22 days after B16 tumor cells inoculation. Data are 5 
representative of three independent experiments. Bars shown are mean ± SD (n=6), 6 
and differences between PBS control group and other groups are determined using 7 
one-way ANOVA analysis and Student’s t test. Relative to control group: *P<0.05, 8 
**P<0.01 and ***P<0.001. 9 
 10 
